Eisai Korea Obtains Sales and Marketing Rights for Excegran
Published: 2005-03-10 06:57:00
Updated: 2005-03-10 06:57:00
Eisai Korea and Dong-A Pharmaceutical recently completed an agreement to transfer the domestic sales and marketing rights for anticonvulsant drug Excegran (active ingredient: zonisamide) from Dong-A to Eisai Korea, effective March 1st.
Developed by Dainippon Pharmaceuticals of Japan, Excegran ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
